Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma

Not many treatment options exist for patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in whom first- and second-line therapies were unsuccessful. This is especially true for patients with aggressive lymphomas. The innovative agent pixantrone has shown some promising resul...

Descripción completa

Detalles Bibliográficos
Autores principales: Jezeršek Novaković, Barbara, Boltežar, Lučka, Novaković, Aleksander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936695/
https://www.ncbi.nlm.nih.gov/pubmed/33688197
http://dx.doi.org/10.2147/TCRM.S269324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936695/
https://www.ncbi.nlm.nih.gov/pubmed/33688197
http://dx.doi.org/10.2147/TCRM.S269324

Ejemplares similares